首页> 美国卫生研究院文献>Cancers >Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study
【2h】

Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study

机译:澳大利亚原发性中枢神经系统淋巴瘤发生率和存活:33年的国家人口研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In Australia, all cancers are recorded in the Australian Cancer Database. We used pathological and anatomical classification codes to identify cases of brain lymphoma—termed primary central nervous system lymphoma or PCNSL—that had occurred in Australia during the past four decades. This allowed us to calculate the incidence of PCNSL, as well as the overall survival after diagnosis with this lymphoma. PCNSL is rare, recently affecting approximately 4 per one million adult Australians per year. However, the number of people diagnosed with this cancer is increasing. Survival of people diagnosed with PCNSL has been improving, but is still low, with only 33% of people alive at 5 years after receiving this diagnosis. As the first survey of the incidence of PCSNL in Australia and the survival of Australians diagnosed with this rare cancer, our research supports current efforts to understand risk factors and improve outcomes.
机译:在澳大利亚,所有癌症都在澳大利亚癌症数据库中记录。我们使用了病理和解剖分类码来鉴定脑淋巴瘤称为原发性神经系统淋巴瘤或PCNSL的病例 - 在过去的四十年中发生在澳大利亚。这使我们能够计算PCNSL的发生率,以及这种淋巴瘤诊断后的整体存活。 PCNSL很少见,最近每年影响每百万成人澳大利亚人大约4个。然而,被诊断患有这种癌症的人数正在增加。诊断出PCNSL的人的生存一直在改善,但仍然很低,只有33%的人在接受这种诊断后5年内活着。作为对澳大利亚PCSNL发病率的第一次调查以及澳大利亚患有这种稀有癌症的澳大利亚人的生存,我们的研究支持目前努力了解风险因素和改善结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号